Evidence map›Paper›PMID 40620493›Full record

ArticleFrontiers in microbiology2025

Where we stand on doxyPEP depends on where we sit: a viewpoint.

Thibaut Vanbaelen, Fabian Kong, Izumo Kanesaka, Sheeba Santhini Manoharan-Basil, Chris Kenyon

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Thibaut VanbaelenSTI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Fabian KongCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.
Izumo KanesakaSTI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Sheeba Santhini Manoharan-BasilSTI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Chris KenyonSTI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a striking variation in national doxycycline post exposure prophylaxis (doxyPEP) guidelines for sexually transmitted infections (STIs). Whilst some countries advocate doxyPEP for all men who have sex with men (MSM) and transgender women (TGW) with certain risks, others restrict the use to research settings. In this viewpoint, we argue that part of the explanation for this divergence can be attributed to different underlying conceptual frameworks. For individuals and organizations dominated by biomedical individualist frameworks, the primary goal of STI services is reducing the incidence of STIs. We have good evidence that doxyPEP does this and therefore, particularly in the setting of increasing STI incidence, this framework regards it as logical to roll out doxyPEP as fast as possible. By way of contrast, if organizations and their members operate within an ecosocial framework then their primary goal is the optimization of the sexual and overall health of individuals and populations and not just reducing STI rates. This framework sees the prevalence of STIs as being driven by the connectivity of local sexual networks. Recent increases in STI prevalence are seen as being due to increased network connectivity. The intensive use of antimicrobials such as doxycycline to reduce this prevalence is seen as introducing a selection pressure for the emergence of resistance to tetracyclines and other antimicrobials in

Indexed as

chlamydiadoxycyclinedoxyPEPgonorrheaSTI - science

Identifiers

PMID40620493
PMCPMC12226477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.